The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases
Allergology International · 2026-07 · 75 (3) · 366-379
DOI: 10.1016/j.alit.2026.01.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergology International, 2026-07. Verfasst von Takashi K Satoh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; Department of Dermat…. Hauptthemen laut MEDLINE: Interleukin-1, Inflammation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, LEO Fondet, Boehringer Ingelheim.
Abstract (Originalsprache)
The interleukin-36 (IL-36) cytokine family is an important regulator of inflammatory responses at epithelial barrier surfaces, with particularly prominent roles in skin immunity and inflammatory disease. As members of the IL-1 superfamily, IL-36 cytokines include three agonists (IL-36α, IL-36β, and IL-36γ) and two antagonists (IL-36Ra and IL-38), which signal through a shared heterodimeric receptor complex to activate MyD88-dependent pathways, including NF-κB and MAPK, and induce pro-inflammatory cytokines, chemokines, and antimicrobial peptides. A defining feature of IL-36 biology is its dependence on proteolytic activation, whereby neutrophil- and pathogen-derived proteases convert low-activity precursors into highly active cytokines, enabling rapid amplification of inflammation and linking epithelial stress to neutrophil recruitment. The clinical relevance of IL-36 signaling was established by the identification of loss-of-function mutations in IL36RN, encoding IL-36Ra, in generalized pustular psoriasis (GPP), a severe and potentially life-threatening neutrophilic dermatosis. These discoveries validated IL-36R as a therapeutic target and culminated in regulatory approval of IL-36R blockade for the treatment of GPP flares. Beyond GPP, accumulating evidence implicates IL-36 in inflammatory processes across multiple organ systems. This review summarizes IL-36 molecular biology, receptor trafficking and signaling, and protease-dependent activation, and discusses roles in barrier immunity and host defense. We also synthesize evidence for pathogenic contributions of IL-36 across inflammatory skin diseases and extra-cutaneous disorders, and highlight emerging therapeutic strategies, biomarkers of response, and future clinical directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; Department of Dermatology and Allergy, University Hospital of Munich (LMU), Munich, German…
- Department of Dermatology, University Hospital Zürich (USZ), University of Zürich (UZH), Zurich, Switzerland.
- Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- LEO Fondet
- Boehringer Ingelheim
Zitieren
APA
Satoh, T. K., Mellett, M., & French, L. E. (2026). The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases. Allergology International, 75(3), 366-379. https://doi.org/10.1016/j.alit.2026.01.006
Vancouver
Satoh TK, Mellett M, French LE. The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases. Allergology International. 2026;75(3):366-379. doi:10.1016/j.alit.2026.01.006
BibTeX
@article{Satoh2026,
author = {Satoh, Takashi K and Mellett, Mark and French, Lars E},
title = {The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases},
journal = {Allergology International},
year = {2026},
volume = {75},
number = {3},
pages = {366--379},
doi = {10.1016/j.alit.2026.01.006}
}
EUVIMED